Literature DB >> 23734968

Seroprevalence of Bordetella pertussis in the Mexican population: a cross-sectional study.

C Conde-Glez1, E Lazcano-Ponce1, R Rojas1, R DeAntonio2, L Romano-Mazzotti3, Y Cervantes3, E Ortega-Barría4.   

Abstract

SUMMARY Serum samples collected during the National Health and Nutrition survey (ENSANUT 2006) were obtained from subjects aged 1-95 years (January-October 2010) and analysed to assess the seroprevalence of Bordetella pertussis (BP) in Mexico. Subjects' gender, age, geographical region and socioeconomic status were extracted from the survey and compiled into a subset database. A total of 3344 subjects (median age 29 years, range 1-95 years) were included in the analysis. Overall, BP seroprevalence was 47.4%. BP seroprevalence was significantly higher in males (53.4%, P = 0.0007) and highest in children (59.3%) decreasing with advancing age (P = 0.0008). BP seroprevalence was not significantly different between regions (P = 0.1918) and between subjects of socioeconomic status (P = 0.0808). Women, adolescents and young adults were identified as potential sources of infection to infants. Booster vaccination for adolescents and primary contacts (including mothers) for newborns and infants may provide an important public health intervention to reduce the disease burden.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23734968      PMCID: PMC9151137          DOI: 10.1017/S0950268813001313

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  32 in total

1.  Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection.

Authors:  Luis A Castagnini; C Mary Healy; Marcia A Rench; Susan H Wootton; Flor M Munoz; Carol J Baker
Journal:  Clin Infect Dis       Date:  2011-11-10       Impact factor: 9.079

2.  Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-10-21       Impact factor: 17.586

3.  The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010.

Authors:  Nicole Guiso; Johannes Liese; Stanley Plotkin
Journal:  Hum Vaccin       Date:  2011-04-01

Review 4.  Pertussis immunisation in adolescents and adults--Bordetella pertussis epidemiology should guide vaccination recommendations.

Authors:  Ulrich Heininger; James D Cherry
Journal:  Expert Opin Biol Ther       Date:  2006-07       Impact factor: 4.388

5.  The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years.

Authors:  L A Cattaneo; G W Reed; D H Haase; M J Wills; K M Edwards
Journal:  J Infect Dis       Date:  1996-05       Impact factor: 5.226

6.  Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.

Authors:  P Olin; F Rasmussen; L Gustafsson; H O Hallander; H Heijbel
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

Review 7.  Epidemiology of pertussis.

Authors:  Tina Tan; Evelinda Trindade; Danuta Skowronski
Journal:  Pediatr Infect Dis J       Date:  2005-05       Impact factor: 2.129

8.  Performance of commercial enzyme-linked immunosorbent assays for detection of antibodies to Bordetella pertussis.

Authors:  M Riffelmann; K Thiel; J Schmetz; C H Wirsing von Koenig
Journal:  J Clin Microbiol       Date:  2010-10-13       Impact factor: 5.948

9.  Pertussis infection in the United States: role for vaccination of adolescents and adults.

Authors:  Dennis A Brooks; Richard Clover
Journal:  J Am Board Fam Med       Date:  2006 Nov-Dec       Impact factor: 2.657

10.  Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.

Authors:  Hans O Hallander; Mikael Andersson; Lennart Gustafsson; Margaretha Ljungman; Eva Netterlid
Journal:  APMIS       Date:  2009-12       Impact factor: 3.205

View more
  6 in total

Review 1.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

2.  Epidemiology of pertussis among adolescents, adults, and older adults in selected countries of Latin American: a systematic review.

Authors:  Altacilio Nunes; Ariane Abreu; Bárbara Furtado; Anderson Soares da Silva; Eduardo B Coelho; Eliana Nc de Barros
Journal:  Hum Vaccin Immunother       Date:  2021-03-18       Impact factor: 3.452

3.  Emerging of ptxP3 lineage in Bordetella pertussis strains circulating in a population in northeastern Mexico.

Authors:  J L Gutiérrez-Ferman; L Villarreal-Treviño; J M Ramírez-Aranda; A Camacho-Ortiz; M R Ballesteros-Elizondo; M R Moreno-Juárez; S Mendoza-Olazarán; M E de la O Cavazos; J Z Villarreal-Pérez; M A Gómez-Govea; E Garza-González
Journal:  Epidemiol Infect       Date:  2018-08-23       Impact factor: 4.434

4.  Seroprevalence of Bordetella pertussis antibodies in adults in Hungary: results of an epidemiological cross-sectional study.

Authors:  Péter Torzsa; Raghavendra Devadiga; Monica Tafalla
Journal:  BMC Infect Dis       Date:  2017-04-04       Impact factor: 3.090

5.  Seroprevalence of Pertussis in Adults at Childbearing Age Pre- and Post- COVID-19 in Beijing, China.

Authors:  Zhiyun Chen; Jie Pang; Yuxiao Zhang; Yiwei Ding; Ning Chen; Nan Zhang; Qiushui He
Journal:  Vaccines (Basel)       Date:  2022-05-29

6.  Seroprevalence of Bordetella pertussis among a nationally representative sample of Iranian pediatric population: The childhood and adolescence surveillance and prevention of adult noncommunicable disease-V study.

Authors:  Zary Nokhodian; Behrooz Ataei; Seyed Mohsen Zahraei; Mohammad Mehdi Gouya; Shervin Ghaffari Hoseini; Majid Yaran; Marjan Mansourian; Mohammad Esmaeil Motlagh; Ramin Heshmat; Roya Kelishadi
Journal:  J Res Med Sci       Date:  2021-03-31       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.